Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

NCT03117933 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

139

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Olaparib
DRUG: Cediranib
DRUG: Paclitaxel

Sponsor

University of Oxford

Collaborators

[object Object]